Clearside Biomedical’s partner signed new collaboration agreement with Santen

Clearside Biomedical (CLSD) announced today that the Company’s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical (SNPHY) for ARVN001, branded in the U.S. as XIPERE, for the treatment of uveitic macular edema and certain other ophthalmic indications under development. Under the terms and conditions of the agreement, Arctic Vision has granted the rights of ARVN001 to Santen to commercialize the product candidate in China excluding Taiwan, Hong Kong and Macau. XIPERE for suprachoroidal use was developed by Clearside and is currently being sold in the United States by Bausch + Lomb.